|Mr. Gregory D. Gorgas||Pres, CEO, CFO, Treasurer, Sec. & Director||581.44k||N/A||1963|
|Mr. Randy Schreckhise||VP of Fin. & Operations||N/A||N/A||N/A|
|Dr. Andrew Yates Ph.D.||Sr. VP, Chief Scientific Officer & Member of Scientific Advisor Board||N/A||N/A||N/A|
|Mr. Peter Michael O'Brien||Sr. VP of European Operations||N/A||N/A||1978|
|Dr. Steven D. Reich||Chief Medical Officer||N/A||N/A||1946|
|Mr. Jason H. Baybutt||Sr. VP of Fin.||N/A||N/A||1972|
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic G protein-coupled receptor agonist, which is in Phase 1 clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for prostate and breast cancer treatment, as well as for treating PTSD. Artelo Biosciences has research collaboration with Trinity College Dublin to Investigate ART27.13 for the treatment of cancer cachexia. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was founded in 2011 and is headquartered in La Jolla, California.
Artelo Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.